Scancell Holdings PLC Sustainability Reports
Scancell Holdings PLC is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company utilizes proprietary technology platforms, including ImmunoBody and Moditope, to design off-the-shelf therapeutic vaccines and monoclonal antibodies.
Sector: Professional & technical services
Country: United Kingdom
Exchange: London Stock Exchange (AIM)
LEI: 2138008RXEG856SNP666
FIGI: BBG001SBYQ98
4 reports from 2022 to 2025